Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Accumulated Expenses (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other Accumulated Expenses for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 123.6% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 123.6% year-over-year, with the annual reading at $2.4 million for FY2025, 123.6% up from the prior year.
  • Other Accumulated Expenses hit $2.4 million in Q4 2025 for Allogene Therapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.4 million in Q4 2025 to a low of $1.1 million in Q4 2024.
  • Historically, Other Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.8 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 63.58% in 2021 and later skyrocketed 123.6% in 2025.
  • Year by year, Other Accumulated Expenses stood at $1.7 million in 2021, then rose by 21.38% to $2.1 million in 2022, then fell by 14.59% to $1.8 million in 2023, then crashed by 40.74% to $1.1 million in 2024, then surged by 123.6% to $2.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for ALLO at $2.4 million in Q4 2025, $1.1 million in Q4 2024, and $1.8 million in Q4 2023.